ORAL ANTICOAGULANTS IN THE TREATMENT OF VENOUS THROMBOEMBOLIC COMPLICATIONS: FOCUS ON APIXABAN

Медицинский совет

E. V. Konstantinova¹  M. Yu. Gilyarov² 

[1] First Moscow State Medical University named after I.M. Sechenov, MoH RF;City Clinical Hospital № 1 named after. N.I. Pirogov, Moscow Healthcare Department;

关键词: apixaban;    venous thromboembolism;    pulmonary embolism;    deep vein thrombosis;    anticoagulants;    vitamin k antagonist;    direct oral anticoagulants;   

DOI  :  10.21518/2079-701X-2017-7-56-62

来源: DOAJ

【 摘 要 】

Venous thromboembolism (VTE), comprising deep vein thrombosis and pulmonary embolism, is a common condition associated with a significant clinical and economic burden. Anticoagulant therapy is the mainstay of treatment for VTE. Current guidelines recommend the use of either low molecular weight heparins or fondaparinux overlapping with and followed by a vitamin K antagonist for the initial treatment of VTE, with the vitamin K antagonist continued when long-term anticoagulation is required. These traditional anticoagulants have practical limitations that have led to the development of direct oral anticoagulants that directly target either Factor Xa or thrombin and are administered at a fixed dose without the need for routine coagulation monitoring. The paper reviews results of the trials of apixaban application for treatment and/or long-term secondary prevention of VTE. The paper analyses effectiveness and safety of apixaban in different groups of patients, as well as features of apixaban application in every day practice.

【 授权许可】

Unknown